Aspergillus Polymerase Chain Reaction: Systematic Review of Evidence for Clinical Use in Comparison With Antigen Testing

作者：White P Lewis^*; Wingard John R; Bretagne Stephane; Loeffler Juergen; Patterson Thomas F; Slavin Monica A; Barnes Rosemary A; Pappas Peter G; Donnelly J Peter

来源：Clinical Infectious Diseases, 2015, 61(8): 1293-1303.

DOI：10.1093/cid/civ507

• Aspergillus
• PCR
• galactomannan
• beta-D-glucan
• aspergillosis

Background. Aspergillus polymerase chain reaction (PCR) was excluded from the European Organisation for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) definitions of invasive fungal disease because of limited standardization and validation. The definitions are being revised.
Methods. A systematic literature review was performed to identify analytical and clinical information available on inclusion of galactomannan enzyme immunoassay (GM-EIA) (2002) and beta-D-glucan (2008), providing a minimal threshold when considering PCR. Categorical parameters and statistical performance were compared.
Results. When incorporated, GM-EIA and beta-D-glucan sensitivities and specificities for diagnosing invasive aspergillosis were 81.6% and 91.6%, and 76.9% and 89.4%, respectively. Aspergillus PCR has similar sensitivity and specificity (76.8%-88.0% and 75.0%-94.5%, respectively) and comparable utility. Methodological recommendations and commercial PCR assays assist standardization. Although all tests have limitations, currently, PCR is the only test with independent quality control.
Conclusions. We propose that there is sufficient evidence that is at least equivalent to that used to include GM-EIA and beta-D-glucan testing, and that PCR is now mature enough for inclusion in the EORTC/MSG definitions.

• 出版日期2015-10-15